 Lapdap chlorproguanil-dapsone is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase G6PD A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap; therefore there is a need to evaluate the extent to which the risks associated with the use of the drug in settings without G6PD screening might outweigh the benefits to malaria treatment. The investigators will evaluate, in operational settings, the safety and effectiveness of Lapdap and coartemether lumefantrine-artemether for treatment of uncomplicated malaria in patients 6 months to 10 years of age. 